吲达帕胺联合氨氯地平治疗高血压伴冠心病的疗效观察被引量：2

下载PDF

导出

摘要目的探讨吲达帕胺联合氨氯地平治疗高血压伴冠心病的临床疗效。方法根据治疗方式不同,将医院收治的60例高血压合并冠心病患者分为治疗组和对照组各30例,治疗组联合应用氨氯地平和吲达帕胺,对照组应用硝苯地平,比较2组临床效果。结果 2组治疗后SBP、DBP值较治疗前均明显下降,且治疗组低于对照组(P<0.05)。治疗组高血压总有效率为86.67%明显高于对照组的63.33%(P<0.05)。治疗组心绞痛总有效率为90.00%明显高于对照组的50.00%,差异均有统计学意义(P<0.05)。2组的不良反应发生率比较差异无统计学意义(P>0.05)。结论临床治疗高血压合并冠心病,联合应用氨氯地平和吲达帕胺可有效控制病情,临床疗效显著,且不良反应少,值得推广应用。

作者周艳芳

机构地区湖南省茶陵县人民医院

出处《临床合理用药杂志》 2015年第23期50-51,共2页 Chinese Journal of Clinical Rational Drug Use

关键词冠心病高血压氨氯地平吲达帕胺

分类号 R544.1 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献7

1汤西双.观察吲达帕胺联合氨氯地平片治疗高血压合并冠心病的临床疗效[J].医学信息（医学与计算机应用）,2014,0(10):480-480. 被引量：4
2邓军华.联合用药对治疗高血压合并冠心病患者的临床效果探讨[J].中国现代药物应用,2013,7(24):108-109. 被引量：6
3张秋平.吲达帕胺治疗40例老年原发性高血压患者临床观察[J].实用临床医药杂志,2011,15(5):78-78. 被引量：1
4李汝奎.吲达帕胺治疗高血压病合并冠心病的临床观察[J].现代医药卫生,2010,26(24):3769-3770. 被引量：10
5余盛龙,陈次滨.氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的疗效观察[J].广东医学,2011,32(18):2458-2460. 被引量：320
6漆军华.氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的临床价值[J].河北医学,2012,18(6):835-837. 被引量：169
7王文,马丽媛,刘明波,邓卿,张宇清,李卫,朱鼎良,林曙光,黄峻,刘力生.初始低剂量氨氯地平加替米沙坦或复方阿米洛利联合治疗对高血压患者血压控制率影响的阶段报告[J].中华心血管病杂志,2009,37(8):701-707. 被引量：86

二级参考文献42

1王鸿懿.高血压合并稳定型冠心病患者中钙拮抗剂的应用[J].中国社区医师,2006,22(13):24-25. 被引量：13
2陈新石.高血压患者控制高血压同时降低胆固醇(联合使用络活喜和立普妥)可降低冠心病死亡和心肌梗死发作的风险[J].中华医学杂志,2007,87(10):717-717. 被引量：23
3卫生部心血管病防治研究中心.中国心血管病报告2006.北京:中国大百科全书出版社,2007.
4Liu L, Zhang Y, Liu G, et al. FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long- term placebo-controlled trial in Chinese hypertensive patients. J Hypertens, 2005,23 : 2157-2572.
5Julius S, Kjeldsen SE, Weber M, et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, 2004,363:2022-2031.
6Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet ,2003,361 : 1149-1158.
7Weber MA, Bakris GL, Dahlof B, et al. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press ,2007,16 : 13-19.
8Wang JG, Li Y, Franklin SS, et al. Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers : a quantitative overview. Hypertension, 2007,50 : 181 - 188.
9Makino H, Haneda M, Babazono T, et al. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes : a post-hoc analysis of The Incipient to Overt: Angiotensin Ⅱ Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study. Hypertens Res,2008,31:657-664.
10Sharma A, Bagchi A, Kinagi SB, et al. Results of a comparative, phase Ⅲ, 12-week, muhicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed- dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage Ⅱ hypertension. Clin Ther, 2007,29 : 2667 -2676.